Fluticasone Topical Information

What's inside Fluticasone Topical

Fluticasone Topical in the News

SkyePharma PLC announces Re Agreement - Market Wire (press release)
FlutiformTM HFA-MDI FlutiformTM HFA-MDI is a fixed-dose combination of formoterol and the inhaled steroid fluticasone in a metered dose inhaler ('MDI'). ...
Thu Dec 20 02:07:06 -0500 2007

Acute Sinusitis—To Treat or Not to Treat? - Journal of American Medical Association (subscription)
Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis: the CAFFS Trial: a randomized controlled trial. JAMA. ...
Tue Dec 04 15:57:43 -0500 2007

skyepharma PLC announces Research Update - Genetic Engineering News (press release)
The Company has eleven approved products in the areas of oral, inhalation and topical delivery. The Group's products are marketed throughout the world by ...
Fri Nov 02 00:25:43 -0400 2007

Fluticasone Topical Chemical Information

fluticasone propionate - The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.